Search

everythinglearnresearchcommunity

for

Search:↓

Most drugs fail to reach the market, but understanding their properties and using strategies like early toxicity tests and drug repurposing can help advance their development.

Stem cell-derived organoids can improve skin healing.

[6]-Gingerdiol 3-monoacetate shows promise for treating T. whipplei infections.

SIG-1451 could be a promising new treatment for atopic dermatitis.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.

Infrared light might help treat stubborn alopecia areata.

Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Correct diagnosis and treatment are crucial for effective management of lipid storage myopathies.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.

New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.

A new lipid-based formula using myristyl myristate can improve estradiol treatment for hair loss.

Aromoline and DRD4 are potential targets for osteoarthritis treatment.

Aumolertinib effectively controls lung cancer and improves quality of life.

Antihepcidin antibodies may treat inflammation-induced anemia by improving iron metabolism.

EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.

Engineered cytokines show promise for improving tissue healing and safety in regenerative medicine.

Erdr1 could be a new marker for diagnosing hair loss.

The patient was satisfied with hormone therapy, and her epilepsy remained stable.

PEA-ENL improves skin delivery and reduces inflammation without side effects.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.